Clinical trials: Pioglitazone, completed
Type 2 Diabetes Mellitus
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications.
- Trial name
- NCT01894568
- Testing
- Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs)
- Where
- 31 sites in Japan, South Korea and 1 more
- Volunteers
- 388 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.
- Trial name
- RAISE (NCT00575874)
- Testing
- Rivoglitazone HCl, pioglitazone HCl
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
PCOS(Insulin Resistant)
Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS
Women with PCOS with HOMA-IR >2 fulfilling inclusion and exclusion criteria are randomly allocated into two groups: group A: pioglitazone 30 mg once daily and group B: Metformin 500 thrice daily for 3 months.Each group contains…
- Trial name
- PCOS HOMA IR (NCT07472179)
- Testing
- Pioglitazone 30 Mg Oral Tablet, metformin 500 mg thrice daily
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Mst.Sumyara Khatun
Chronic Hepatitis C
Pioglitazone in Hepatitis C
The presence of insulin resistance (IR) appears to be a key factor in the development of steatosis and disease progression in patience with Hepatitis C virus (HCV) genotype-1 infections similar to levels in Non-alcoholic fatty…
- Trial name
- NCT00189163
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 26.
- Trial name
- EPIDOTE (NCT03499704)
- Testing
- Pioglitazone + Alogliptin, Alogliptin, Metformin
- Where
- 15 sites in South Korea
- Volunteers
- 133 people
- Sponsor
- Celltrion Pharm, Inc.
Type 2 Diabetes Mellitus
30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
A 30-week extension to a 24-week study assessing the hemoglobin A1c (HbA1c)- and fasting plasma glucose (FPG)-lowering efficacy of the combination of sitagliptin and pioglitazone in patients with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT01028391
- Testing
- Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d., Metformin
- Volunteers
- 317 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone
This study will assess the safety and efficacy of adding nateglinide to treatment with basal insulin glargine, metformin and/or thiazolidinedione (pioglitazone or rosiglitazone), for patients with type 2 diabetes who are not…
- Trial name
- NCT00402909
- Testing
- Nateglinide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Pharmacokinetics of MDV3100, Castration Resistant Prostate Cancer (CRPC)
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19…
- Trial name
- NCT01911728
- Testing
- MDV3100, Pioglitazone, Warfarin
- Where
- 2 sites in South Africa
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Europe B.V.
Type 2 Diabetes
Pharmacogenomics of Thiazolidinediones
The purpose of this study is to determine predictors of response to pioglitazone, an anti-diabetic medication. The investigators know from randomized clinical trials that some 30% of patients do not respond to this type of…
- Trial name
- PPAR (NCT01135394)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
- Trial name
- NCT00839527
- Testing
- albiglutide, metformin, glimepiride
- Where
- 358 sites in United States, Germany and 7 more
- Volunteers
- 685 people
- Sponsor
- GlaxoSmithKline
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Antidiabetic Drugs for Steatotic Liver Disease
To investigate the synergic therapeutic effect of thiazolidinediones and SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease, the effect of empagliflozin 10mg, pioglitazone 15mg monotherapy and combination…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases
- Trial name
- NCT03646292
- Testing
- Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University
Type 2 Diabetes Mellitus
Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2
The purpose of this study is to improve blood glucose control in Type 2 Diabetes mellitus patients.
- Trial name
- NCT01065298
- Testing
- stem cell transplantation
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Rheumatoid Arthritis, Insulin Resistance
Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)
Muscle strength helps determine a person's quality of life and functional independence. Patients with rheumatoid arthritis often suffer from muscle weakness and a pre-diabetic condition called insulin resistance.
- Trial name
- NCT02535832
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Type 2 Diabetes Mellitus, Insulin Resistance
Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin
The goal of the study is to demonstrate whether a switch from insulin therapy to an oral therapy with pioglitazone/glimepiride will lead to a deterioration of glycemic control (increase in HbA1c by more than 0.5 %) within a 6…
- Trial name
- PIOswitch (NCT00576784)
- Testing
- pioglitazone and glimepiride
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- IKFE Institute for Clinical Research and Development
Hepatitis
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol.
- Trial name
- NCT00062764
- Testing
- Actos (Pioglitazone)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Steatohepatitis
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes (T2DM) and characterized by insulin resistance and hepatic fat accumulation.
- Trial name
- VA NASH (NCT01002547)
- Testing
- pioglitazone, Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent…
- Trial name
- NCT01697592
- Testing
- Omarigliptin
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Fibrosis
Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone
Liver cirrhosis (LC) is the final destiny in chronic liver disease. Liver transplantation is the only effective therapy available to these patients.
- Trial name
- NCT01454336
- Testing
- Cell injection
- Where
- Iran
- Volunteers
- 3 people
- Sponsor
- Royan Institute
Lung Cancer, Endobronchial Dysplasia
Pioglitazone for Lung Cancer Chemoprevention
This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either…
- Trial name
- NCT00780234
- Testing
- fluorescence bronchoscopy, quantitative high resolution CT scan
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes.
- Trial name
- AWARD-1 (NCT01064687)
- Testing
- LY2189265, Exenatide, Metformin
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 978 people
- Sponsor
- Eli Lilly and Company